Amphivena Therapeutics, a subsidiary of Affimed Therapeutics, develops treatments to address hematologic malignancies. Founded by Jeanmarie Guenot and Luke Evnin in 2012, Amphivena Therapeutics is backed by investors that include Aju IB Investment, Merieux Developpement, MPM Capital, NanoDimension, and Qiming Venture Partners and is headquartered in San Francisco.